Calcinosis Cutis and Calciphylaxis in Autoimmune Connective Tissue Diseases

Overview

Journal Vaccines (Basel)

Date 2023 May 27

PMID 37243003

Authors

Ilaria Mormile

Francesca Mosella

Piergiorgio Turco

Filomena Napolitano

Amato De Paulis

Francesca Wanda Rossi

Affiliations

Soon will be listed here.

Abstract

Calcinosis represents a severe complication of several autoimmune disorders. Soft-tissue calcifications have been classified into five major types: dystrophic, metastatic, idiopathic, iatrogenic, and calciphylaxis. Autoimmune diseases are usually associated with dystrophic calcifications, including calcinosis cutis, occurring in damaged or devitalized tissues in the presence of normal serum levels of calcium and phosphate. In particular, calcinosis cutis has been described in dermatomyositis, polymyositis, juvenile dermatomyositis, systemic sclerosis, systemic lupus erythematosus, primary Sjögren's syndrome, overlap syndrome, mixed connective tissue disease, and rheumatoid arthritis. Calciphylaxis, a severe and life-threatening syndrome presenting with vascular calcifications and thrombosis, has also been associated with some autoimmune conditions. Due to the potentially disabling character of calcinosis cutis and calciphylaxis, physicians' awareness about the clinical presentation and management of these diseases should be increased to select the most appropriate treatment option and avoid long-term complications. In this review, we aim to analyze the clinical features of calcinosis cutis and calciphylaxis associated with autoimmune diseases, and the main treatment strategies evaluated up to now for treating this potentially disabling disease.

Citing Articles

Chilblain lupus erythematosus associated with erdafitinib therapy in a patient with metastatic bladder cancer.

Truong A, Liu J, Ni C, Yashar S JAAD Case Rep. 2024; 54:62-65.

PMID: 39654848 PMC: 11626054. DOI: 10.1016/j.jdcr.2024.10.007.

Treatment of Calcinosis in Dermatomyositis-Case Report and Review.

Fraczek A, Kuna J, Rybak dObyrn J, Krajewska-Wlodarczyk M, Owczarczyk-Saczonek A J Clin Med. 2024; 13(20).

PMID: 39458184 PMC: 11508430. DOI: 10.3390/jcm13206234.

Calcinosis Prevalence in Autoimmune Connective Tissue Diseases-A Retrospective Study.

Robert L, Nemeth K, Marschalko M, Hollo P, Hidvegi B J Clin Med. 2024; 13(12).

PMID: 38929957 PMC: 11204081. DOI: 10.3390/jcm13123428.

Calcinosis in Rheumatic Disease Is Still an Unmet Need: A Retrospective Single-Center Study.

Nita C, Groseanu L, Opris D, Predeteanu D, Bojinca V, Berghea F Diagnostics (Basel). 2024; 14(6).

PMID: 38535057 PMC: 10969174. DOI: 10.3390/diagnostics14060637.

Imaging diagnosis and differential diagnosis of extraskeletal osteosarcoma.

Wang X, Zhang L, Lin J, Huang X, Liang J, Zhong J BMC Cancer. 2024; 24(1):11.

PMID: 38166700 PMC: 10763387. DOI: 10.1186/s12885-023-11731-3.

References

Findlay A, Goyal N, Mozaffar T . An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015; 51(5):638-56. DOI: 10.1002/mus.24566. View

Hughes M, Herrick A . Diagnosis and management of systemic sclerosis-related calcinosis. Expert Rev Clin Immunol. 2022; 19(1):45-54. DOI: 10.1080/1744666X.2023.2144835. View

Giuggioli D, Lumetti F, Colaci M, Fallahi P, Antonelli A, Ferri C . Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev. 2015; 14(11):1072-8. DOI: 10.1016/j.autrev.2015.07.008. View

Petrelli F, Mariani F, Alunno A, Puxeddu I . Pathogenesis of rheumatoid arthritis: one year in review 2022. Clin Exp Rheumatol. 2022; 40(3):475-482. DOI: 10.55563/clinexprheumatol/l9lyen. View

Agrawal R, Agrawal J, Agrawal B, Nath A, Agrawal A, Gaddipat J . Some unusual paraneoplastic syndromes. Case 3. Metastatic pulmonary calcification causing hypoxemia in male breast cancer. J Clin Oncol. 2003; 21(13):2622-4. DOI: 10.1200/JCO.2003.09.104. View

Hoeltzel M, Oberle E, Robinson A, Agarwal A, Rider L . The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep. 2014; 16(12):467. PMC: 5118224. DOI: 10.1007/s11926-014-0467-y. View

Morgan N, Shah A, Mayes M, Domsic R, Medsger Jr T, Steen V . Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database. Medicine (Baltimore). 2018; 96(51):e8980. PMC: 5758130. DOI: 10.1097/MD.0000000000008980. View

Richardson C, Plaas A, Varga J . Calcinosis in Systemic Sclerosis: Updates in Pathophysiology, Evaluation, and Treatment. Curr Rheumatol Rep. 2020; 22(10):73. DOI: 10.1007/s11926-020-00951-2. View

Bhatia S, Silverberg N, Don P, Weinberg J . Extensive calcinosis cutis in association with systemic lupus erythematosus. Acta Derm Venereol. 2002; 81(6):446-7. DOI: 10.1080/000155501317208516. View

10.

Badawi A, Patel V, Warner A, Hall J . Dystrophic calcinosis cutis: treatment with intravenous sodium thiosulfate. Cutis. 2020; 106(2):E15-E17. DOI: 10.12788/cutis.0071. View

11.

Marcondes F, Scheinberg M . Belimumab in the treatment of systemic lupus erythematous: An evidence based review of its place in therapy. Autoimmun Rev. 2017; 17(2):103-107. DOI: 10.1016/j.autrev.2017.11.013. View

12.

Napolitano F, Postiglione L, Mormile I, Barrella V, De Paulis A, Montuori N . Water from Nitrodi's Spring Induces Dermal Fibroblast and Keratinocyte Activation, Thus Promoting Wound Repair in the Skin: An In Vitro Study. Int J Mol Sci. 2023; 24(6). PMC: 10049109. DOI: 10.3390/ijms24065357. View

13.

Geissler B, Agaimy A, Jungert J, Hartmann A, Carbon R, Knorr C . Tumoral calcinosis of the gluteal region in a 14-year-old girl with juvenile polyarthritis. Eur J Pediatr Surg. 2010; 20(6):421-3. DOI: 10.1055/s-0030-1254120. View

14.

Tsuchida Y, Sumitomo S, Fujio K, Yamamoto K . Massive calcinosis cutis associated with primary Sjögren's syndrome. BMJ Case Rep. 2016; 2016. PMC: 4746507. DOI: 10.1136/bcr-2015-214006. View

15.

Hida T, Minami M, Kubo Y . Bilateral leg ulcers secondary to dystrophic calcinosis in a patient with rheumatoid arthritis. J Med Invest. 2017; 64(3.4):308-310. DOI: 10.2152/jmi.64.308. View

16.

Chung M, Richardson C, Kirakossian D, Orandi A, Saketkoo L, Rider L . Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis. Autoimmun Rev. 2020; 19(6):102533. PMC: 7225028. DOI: 10.1016/j.autrev.2020.102533. View

17.

Cutolo M, Soldano S, Smith V . Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin Immunol. 2019; 15(7):753-764. DOI: 10.1080/1744666X.2019.1614915. View

18.

Lowry C, Pilkington C . Juvenile dermatomyositis: extramuscular manifestations and their management. Curr Opin Rheumatol. 2009; 21(6):575-80. DOI: 10.1097/BOR.0b013e328331927e. View

19.

Belloli L, Ughi N, Massarotti M, Marasini B, Biondi M, Brambilla G . Role of fetuin-A in systemic sclerosis-associated calcinosis. J Rheumatol. 2010; 37(12):2638-9. DOI: 10.3899/jrheum.100627. View

20.

Sabbagh S, de Jesus A, Hwang S, Kuehn H, Kim H, Jung L . Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019; 142(11):e59. PMC: 6821280. DOI: 10.1093/brain/awz293. View